<DOC>
	<DOCNO>NCT02260557</DOCNO>
	<brief_summary>The primary objective study determine activity selexipag Raynaud attack frequency subject Raynaud 's Phenomenon ( RP ) secondary Systemic Sclerosis ( SSc ) .</brief_summary>
	<brief_title>Effects Selexipag Adults With Raynaud 's Phenomenon Secondary Systemic Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Raynaud Disease</mesh_term>
	<mesh_term>Selexipag</mesh_term>
	<criteria>Key inclusion criterion : Signed informed consent prior studymandated procedure . Male female subject age 18 year history recurrent multiple weekly RP attack secondary SSc . Women childbearing potential must agree use reliable method birth control . Key exclusion criterion : Known moderate severe hepatic impairment ( i.e . ChildPugh C ) . Known hypersensitivity selexipag drug class , excipients . Subjects receive prostacyclin ( epoprostenol ) prostacyclin analog ( i.e. , treprostenol , iloprost , beraprost ) within 3 month prior screen visit . Subjects received Phosphodiesterase type 5 ( PDE5 ) inhibitor within 1 week prior screen visit . Any dose change initiation follow drug within 1 month prior screen visit : Calcium channel blocker , Nitrates nitric oxide donor , ERA 's , Alphablockers , Antithrombotic agent , NSAIDs ( occasional use allow ) , Angiotensin Converting Enzyme ( ACE ) inhibitor , Betablockers , Clonidine , Systemic corticosteroid , Fluoxetine . Severe renal insufficiency ( randomization ) . Any circumstance condition , , opinion investigator , may affect subject 's full participation study compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Systemic Sclerosis</keyword>
	<keyword>Raynaud 's Phenomenon</keyword>
</DOC>